Newer modalities such as T cell engagers, which are bispecific antibodies that simultaneously bind with the T-cell and the tumor cell, are mostly in preclinical or early phase, while cytokine-based therapies, have progressed to later phases of development given its approved use in other cancers such as melanoma, particularly peginterferon alfa-2b and interleukin-2. The gene discussed is IL2; the disease is cancer.